visualvisitorlogo
  • Our Platform downarrow
    Powerful Sales
    Intelligence     dashboard
    Platform Overview
    Buyer Intent Data
    B2B Prospect Data     Website Visitor ID Email Tracking
  • Why?downarrow
    Your Challenges Our Data See For Yourself
  • Pricing
  • Resourcesdownarrow
    Resellers
    Add Onsdrop
    Call Tracking     Keyword Level Tracking Reputation Management
    Integrations About Us
    Contactdrop
    Atlanta Jacksonville
    Blog Careers Support
    • Login Free Trial Schedule A Demo
    × Our Platform downarrow
    Why? downarrow
    Pricing Resources downarrow
    visualvisitorlogo ☰

    Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting

    Get Full Access

    Description

    • The DuraGraft® Difference: DuraGraft is a vascular graft treatment that improves clinical outcomes by reducing the incidence and complications of graft failure. Challenge: VGD | VGF-----------------------------~ Intraoperative Graft Damage is the Principal Cause of Vein Graft Failure.~ The durability and patency of vein grafts are significantly compromised by Vein Graft Disease (VGD):VGD | VGF ~ Causes----------------------------~ VGD process begins during the grafting surgery itself (1)~ Surgical factors are associated with subsequent development of Vein Graft Failure (VGF)~ VGD is the principal cause of both early (within 30 days) and intermediate/late VGF~ VGD encompasses the pathophysiological changes that occur in vein grafts following their use in surgical graftingVGD | VGF ~ Effects--------------------------1. Endothelial Damage, Manifested Within Minutes as Pro-inflammatory, Pro-thrombogenic, and Hyper-proliferative Changes Within the Graft, Leads to VGD2. As VGD progresses, vein grafts lose their ability to adapt to the post-grafting environment, leading to: Thrombus formation Intimal hyperplasia Atherosclerosis3. These may result in: Graft Stenosis Occlusion Loss of Graft PatencyDuraGraft is not available in all markets. Visit somahlution.com/distributors for availability.
    • location

      Headquarters:225 Chimney Corner Ln Ste 2001 Suite 2001, Jupiter, Florida, United States

      More
    • Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting phone

      Phone Number: +1 561-935-9955

    • Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting website

      Website: https://www.somahlution.com

    • Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting employees

      Employees:24

    • Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting revenue

      Revenue:$10 - 50M

    • Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting legal name

      Legal Name:Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting

    • Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting's Social Media

      Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting linkedin
    • done Is this data correct?

    • |  NAICS Code: 453998  |

      Show More
    Person level website identification

    Chief Scientific Officer for Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting

    Catherine Pachuk

    Chief Scientific Officer

    Person level website visitor identification

    Sell more in less time!

    Buyer intent data, anonymous visitor identification, first party data integration backed by a massive contact database that will supercharge your sales team. Schedule a demo to learn more!

    View Employees

    Catherine Pachuk

    Chief Scientific Officer

    Amar Dhaduk

    Vice President Business Affairs At Somahlution

    Amy Chandler

    Consultant Senior Director Regulatory Affairs And Qa

    Vilas Satish

    Director, Global Clinical Affairs

    Cheryl Rosenbeger

    Manager, Analytical Services

    Frequently Asked Questions regarding Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting

    • Where are Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting's Headquarters?

      Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting's Headquarters are in 225 Chimney Corner Ln Ste 2001 Suite 2001,Jupiter,Florida,United States

    • What is Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting's phone number?

      Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting's phone number is +1 561-935-9955

    • What is Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting's official website?

      Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting's official website is https://www.somahlution.com

    • What is Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting's Revenue?

      Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting's revenue is $10 - 50M

    • What is Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting's NAICS code?

      Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting's NAICS code is 453998

    • How many employees are working in Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting

      Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting has 24 employees

    • What is Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting's Industry?

      Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting is in the industry of Biotechnology

    • Who is Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting's Chief Scientific Officer?

      Somahlution: Duragraft Vascular Graft Treatment Improves Outcomes In Coronary Artery Bypass Grafting's Chief Scientific Officer is Catherine Pachuk

    Company Directory